REFERENCES
-
1
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group .
Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med.
1995;
333
1581-1587
-
2
Katzan I L, Furlan A J, Lloyd L E et al..
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
JAMA.
2000;
283
1151-1158
-
3
Katzan I L, Hammer M D, Furlan A J, Hixson E D, Nadzam D M.
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Stroke.
2003;
34
799-800
-
4
Johnston S C, Fung L H, Gillum L A et al..
Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity.
Stroke.
2001;
32
1061-1068
-
5
Katzan I L, Hammer M D, Hixson E D, Furlan A J, Abou-Chebl A, Nadzam D M.
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
Arch Neurol.
2004;
61
346-350
-
6
Johnston S C, Gress D R, Browner W S, Sidney S.
Short-term prognosis after emergency department diagnosis of TIA.
JAMA.
2000;
284
2901-2906
-
7
Kleindorfer D, Panagos P, Pancioli A et al..
Incidence and short-term prognosis of transient ischemic attack in a population-based study.
Stroke.
2005;
36
720-723
-
8
Rothwell P M, Warlow C P.
Timing of TIAs preceding stroke: time window for prevention is very short.
Neurology.
2005;
64
817-820
-
9
van Wijk I, Kappelle L J, van Gijn J et al..
Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study.
Lancet.
2005;
365
2098-2104
-
10
Chaturvedi S.
Should the multicenter carotid endarterectomy trials be repeated?.
Arch Neurol.
2003;
60
774-775
-
11
Williams L S, Brizendine E J, Plue L et al..
Performance of the PHQ-9 as a screening tool for depression after stroke.
Stroke.
2005;
36
635-638
-
12
Williams L S, Ghose S S, Swindle R W.
Depression and other mental health diagnoses increase mortality risk after ischemic stroke.
Am J Psychiatry.
2004;
161
1090-1095
-
13
Fullerton H J, Wu Y W, Zhao S, Johnston S C.
Risk of stroke in children: ethnic and gender disparities.
Neurology.
2003;
61
189-194
-
14
Lee J, Croen L A, Backstrand K H et al..
Maternal and infant characteristics associated with perinatal arterial stroke in the infant.
JAMA.
2005;
293
723-729
-
15
Wu Y W, March W M, Croen L A, Grether J K, Escobar G J, Newman T B.
Perinatal stroke in children with motor impairment: a population-based study.
Pediatrics.
2004;
114
612-619
-
16
Lynch J K, Hirtz D G, DeVeber G, Nelson K B.
Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke.
Pediatrics.
2002;
109
116-123
-
17
Nelson K B, Lynch J K.
Stroke in newborn infants.
Lancet Neurol.
2004;
3
150-158
-
18
Flibotte J J, Hagan N, O'Donnell J, Greenberg S M, Rosand J.
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.
Neurology.
2004;
63
1059-1064
-
19
Greenberg S M, Eng J A, Ning M, Smith E E, Rosand J.
Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage.
Stroke.
2004;
35
1415-1420
-
20
Rosand J, Greenberg S M.
Beyond hypertension: unraveling the causes of intracerebral hemorrhage.
Stroke.
2002;
33
1195-1196
-
21
Mayer S A, Brun N C, Begtrup K et al..
Recombinant activated factor VII for acute intracerebral hemorrhage.
N Engl J Med.
2005;
352
777-785
Bradford B WorrallM.D. M.Sc.
Department of Neurology, University of Virginia, HSC 800394, Charlottesville, VA 22908-0001
